Table 1 The characteristics of all patients.

From: Associations between Left Ventricular Cavity Size and Cardiac Function and Overload Determined by Natriuretic Peptide Levels and a Covariance Structure Analysis

Characteristics

Overall (n = 1715)

IHD (n = 1363)

Non-IHD (n = 352)

Number (%) or Mean ± SD [Median; interquartile range]

Gender; Male

1397 (81.5)

1161 (85.2)

236 (67.0)

Age (years old)

64.6 ± 11.5

65.1 ± 10.9

62.7 ± 13.4

BMI (kg/m2)

24.3 ± 4.1

24.6 ± 4.0

23.3 ± 4.4

Current smoker

386 (22.5)

313 (23.0)

73 (20.7)

Family history of IHD

445 (26.1)

372 (27.3)

73 (20.7)

Hb (g/dL)

13.3 ± 2.0

13.3 ± 1.9

13.5 ± 2.3

Creatinine (mg/dL)

1.66 ± 2.54

1.72 ± 2.65

1.42 ± 2.03

eGFR (mL/min/1.73 m2)

64.8 ± 26.3

64.9 ± 26.6

64.6 ± 25.1

UA (mg/dL)

6.0 ± 1.5

5.9 ± 1.4

6.3 ± 1.9

FBS (mg/dL)

120.4 ± 39.6

123.1 ± 41.4

110.0 ± 29.0

HbA1c (%)

6.2 ± 1.1

6.3 ± 1.1

5.9 ± 0.9

TG (mg/dL)

124.5 ± 103.7

127.9 ± 110.9

111.3 ± 67.9

HDL-C (mg/dL)

51.9 ± 15.7

51.1 ± 15.2

55.2 ± 16.9

LDL-C (mg/dL)

102.9 ± 31.4

101.4 ± 30.8

108.4 ± 33.1

LDL-C/HDL-C

2.14 ± 0.92

2.14 ± 0.87

2.15 ± 1.08

CRP (mg/dL)

0.58 ± 1.61

0.57 ± 1.66

0.61 ± 1.41

BNP (pg/mL)

[48.0; 17.4–153.8]

[38.7; 15.4–123.3]

[103.7; 34.6–243.0]

Left ventricular hemodynamic parameters

LVEDVI (mL/m2)

68.4 ± 23.9

64.8 ± 19.3

82.0 ± 33.2

LVESVI (mL/m2)

31.6 ± 19.4

28.9 ± 15.7

42.0 ± 27.4

LVEF (%)

56.1 ± 12.1

57.2 ± 10.8

51.8 ± 15.3

LVEDP (mmHg)

17.1 ± 8.5

16.9 ± 8.7

17.9 ± 7.8

SVI (ml/m²)

39.2 ± 12.2

39.2 ± 12.0

39.2 ± 12.3

Underlying cardiovascular disease

Ischemic heart disease

1363 (79.5)

1363

—

Acute coronary syndrome

113 (6.6)

113 (8.3)

—

Angina pectoris

1216 (70.9)

1216 (89.2)

—

Cardiomyopathy

168 (9.8)

33 (2.4)

135 (38.4)

Valvular disease

191 (11.1)

71 (5.2)

120 (34.1)

Arrhythmia

133 (7.8)

58 (4.3)

75 (21.3)

Atrial fibrillation

112 (6.5)

44 (3.2)

68 (19.3)

Other than AF

21 (1.2)

14 (1.0)

7 (2.0)

Hypertension

1269 (74.0)

1049 (77.0)

220 (62.5)

Type-2 diabetes mellitus

647 (37.7)

566 (41.5)

81 (23.0)

Dyslipidemia

1239 (72.2)

1077 (79.0)

162 (46.0)

Renal dysfunction*

554 (32.3)

428 (31.4)

126 (35.8)

Hemodialysis

179 (10.4)

150 (11.0)

29 (8.2)

Medication

Antiplatelet agent

1158 (67.5)

1057 (77.5)

101 (28.7)

Anticoagulant agent

170 (9.9)

101 (7.4)

69 (19.6)

ACE inhibitors

301 (17.6)

256 (18.8)

45 (12.8)

ARBs

647 (37.7)

545 (40.0)

102 (29.0)

Beta blockers

633 (36.9)

537 (40.0)

96 (27.3)

Calcium channel blockers

923 (53.8)

804 (59.0)

119 (33.8)

Diuretics

320 (18.7)

216 (15.8)

104 (29.5)

Statins

904 (52.7)

824 (60.5)

80 (22.7)

Non- Statin for dyslipidemia

223 (13.0)

199 (14.6)

24 (6.8)

Oral antidiabetic agents

402 (23.4)

355 (26.0)

47 (13.4)

Insulin

177 (10.3)

157 (11.5)

20 (5.7)

Anti-hyperuricemia

280 (16.3)

220 (16.1)

60 (17.0)

  1. Hb, hemoglobin; UA, uric acid; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; TG, triglycerides; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; ACE, angiotensin-converting enzyme; ARBs, angiotensin II type I-receptor blockers; BMI, body mass index; BNP, B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; LVEDP, left ventricular end-diastolic pressure; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; and SVI, stroke volume index.
  2. *Renal dysfunction = eGFR < 60 mL/min/1.73 m2.
Back to article page